Rubi K. Li

1.4k total citations
9 papers, 666 citations indexed

About

Rubi K. Li is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rubi K. Li has authored 9 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rubi K. Li's work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Rubi K. Li is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Rubi K. Li collaborates with scholars based in Philippines, United States and South Korea. Rubi K. Li's co-authors include Hyun Cheol Chung, Henri Roché, Jacek Jassem, Valorie F. Chan, Luis Fein, Xavier Pivot, Guillermo Lerzo, Linda T. Vahdat, Henry Gómez and P. Mukhopadhyay and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Rubi K. Li

9 papers receiving 650 citations

Peers

Rubi K. Li

ONCOL

IMMUN

PRM

RNMI

J.-M. Nabholtz Canada

Jin‐Hee Ahn South Korea

F Penault–Llorca France

Martin Olivo United States

C. Hudis United States

Gustavo Ismael Belgium

Reshma Mahtani United States

Patricia Gómez Spain

Ulla Wilking Sweden

R. Mione Italy

J.-M. Nabholtz Canada

Rubi K. Li

518 ×0.9

ONCOL

209 ×1.1

103 ×0.8

IMMUN

86 ×0.8

PRM

110 ×1.0

RNMI

Citations per year, relative to Rubi K. Li Rubi K. Li (= 1×) peers J.-M. Nabholtz

Countries citing papers authored by Rubi K. Li

Since Specialization

Citations

This map shows the geographic impact of Rubi K. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rubi K. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rubi K. Li more than expected).

Fields of papers citing papers by Rubi K. Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rubi K. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rubi K. Li. The network helps show where Rubi K. Li may publish in the future.

Co-authorship network of co-authors of Rubi K. Li

This figure shows the co-authorship network connecting the top 25 collaborators of Rubi K. Li. A scholar is included among the top collaborators of Rubi K. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rubi K. Li. Rubi K. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Li, Rubi K., Eriko Tokunaga, Hryhoriy Adamchuk, et al.. (2022). Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study. BioDrugs. 36(1). 55–69. 12 indexed citations

Stebbing, Justin, Alexey Manikhas, Vladimir Moiseyenko, et al.. (2021). Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment. 188(3). 631–640. 15 indexed citations

Li, Rubi K., Oleg Lipatov, Hryhoriy Adamchuk, et al.. (2020). Abstract P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data. Cancer Research. 80(4_Supplement). P1–18. 2 indexed citations

Pegram, Mark D., Igor Bondarenko, Hirotaka Iwase, et al.. (2018). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer. 120(2). 172–182. 50 indexed citations

Stebbing, Justin, Alexey Manikhas, Vladimir Moiseyenko, et al.. (2017). CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. The Lancet Oncology. 18(7). 917–928. 94 indexed citations

Lee, Se‐Hoon, Yung‐Jue Bang, Paul N. Mainwaring, et al.. (2014). Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. Asia-Pacific Journal of Clinical Oncology. 10(3). 237–245. 36 indexed citations

Hortobágyi, Gabriel N., Henry Gómez, Rubi K. Li, et al.. (2010). Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment. 122(2). 409–418. 54 indexed citations

Pivot, Xavier, Rubi K. Li, Eva Thomas, et al.. (2009). Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. European Journal of Cancer. 45(17). 2940–2946. 20 indexed citations

Thomas, E. Donnall, Henry Gómez, Rubi K. Li, et al.. (2007). Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology. 25(33). 5210–5217. 383 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact